Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anika Therapeutics Q4 net income declines
Net income for the year ended December 31, 2008 was $3.63 million, or $0.32 per diluted share, compared with $6.04 million, or $0.53 per diluted share in 2007.
Net income for the year ended December 31, 2008 was $3.63 million, or $0.32 per diluted share, compared with $6.04 million, or $0.53 per diluted share in 2007.
GPC Biotech, a publicly traded biopharmaceutical company, has reported encouraging data from the double-blind, randomized satraplatin Phase III trial, the Sparc trial. The Sparc trial evaluated satraplatin plus
Amicus Therapeutics, a biopharmaceutical company, has suspended enrollment for the Phase II clinical trial of its investigational drug AT2220 for the treatment of Pompe disease and that it
Cephalon, a biopharmaceutical company, has announced that its wholly-owned subsidiary, Cephalon International Holdings, intends to make a takeover offer for Australia-based biotechnology company Arana Therapeutics. Under its bid,
Pluristem Therapeutics has announced that the FDA has cleared the company’s investigational new drug application to initiate a Phase I clinical trial for the treatment of critical limb
Power Medical Interventions, a developer of surgical instruments, has received a $2.5m payment from Intuitive Surgical, a developer of minimally invasive surgery systems. The payment to Power Medical
Fourth quarter revenues declined from third quarter levels due to delayed recognition of contract revenue, exchange rate impacts and seasonality. Total revenues for the fourth quarter of 2008
Winner Medical Group, a manufacturer of medical and wound care products, has announced that the European Patent Office has decided to grant the patent for producing PurCotton products
Net loss applicable to common shares for the year ended December 31, 2008 was $42.3 million, or $2.47 per basic and diluted share, compared to a net loss
Cell Genesys, a biotechnology company, has announced positive results from further analyses of Vital-1, the company’s recently terminated Phase III clinical trial which compared Gvax immunotherapy for prostate